[1]Zheng J,Xie GY,Li J,et al.Clinical significance of EGFR mutations in non-small cell lung cancer[J].Chin J Clin Oncol,2014,41(14):904-907.[郑军,谢贵元,李姣,等.非小细胞肺癌EGFR基因突变的临床意义研究[J].中国肿瘤临床,2014,41(14):904-907.]
[2]Jin LF,Qi XW,Lu L,et al.EGFR and K-ras gene mutation in non-small cell lung cancer[J].Modern Oncology,2016,24(8):1218-1221.[金琳芳,齐晓薇,陆莲,等.非小细胞肺癌中EGFR和K-ras基因突变检测[J].现代肿瘤医学,2016,24(8):1218-1221.]
[3]Yu W,Liang JP,Yang DS,et al.Analysis on the EGFR mutation test results of 100 sequential patients with primary bronchogenic carcinoma[J].Anti-tumor Pharmacy,2016,6(2):150-153.[喻巍,梁剑平,杨德松,等.连续100例肺癌术后EGFR基因突变检测结果分析[J].肿瘤药学,2016,6(2):150-153.]
[4]Keam B,Kim DW,Park JH,et al.Rare and complex mutations of epidermal growth factor receptor,and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer[J].Int J Clin Oncol,2014,19(4):594-600.
[5]Zhang L,Wu N,Li M,et al.The effective mutation of epidermal growth factor receptor in early lung adenocarcinomas:study of clinical,radiographic,and pathological factors[J].Oncology Progress,2016,14(5):432-437.[张丽,吴宁,李蒙,等.早期肺腺癌EGFR基因突变的相关因素研究[J].癌症进展,2016,14(5):432-437.]
[6]Kim GW,JS Song,CM Choi,et al.Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival[J].Lung Cancer,2015,88(2):139-146.
[7]Yao YF,Wang BC,Wang J.Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer patients harboring EGFR mutations[J].Modern Oncology,2016,24(6):981-984.[姚云峰,王宝成,王俊.酪氨酸激酶抑制剂在非小细胞肺癌中的耐药机制[J].现代肿瘤医学,2016,24(6):981-984.]
[8]Chiu CH,Yang CT,Shih JY,et al.Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with g719x/l861q/s768i mutations[J].J Thoracic Oncology,2015,10(5):793-799.
[9]Wang JH,Li JP,Jin MW,et al.Detection of EGFR gene 19 and 21 exons mutations in non-small cell lung cancer by Sanger sequencing versus amplification refractory mutation system assay[J].Zhejiang Medical Journal,2017,39(2):97-101.[王建华,李纪鹏,金明威,等.Sanger测序法和突变扩增阻滞系统法检测非小细胞肺癌EGFR基因19、21 号外显子突变的临床价值比较[J].浙江医学,2017,39(2):97-101.]
[10]Sun YJ,Liu C,Long Y,et al.Comparison between ADx-ARMS and PCR-Sanger sequencing for EGFR mutation detection in small biopsy samples of non-small cell lung cancer[J].Chinese J Clinical Laboratory Science,2014,32(7):485-489.[孙宇晶,刘畅,龙彦,等.ADx-ARMS法与PCR-Sanger测序法检测非小细胞肺癌微小标本EGFR基因突变的比较[J].临床检验杂志,2014,32(7):485-489.]
[11]Dong QG,Han BH,Huang JS,et al.Analysis of EGFR mutations in 176 cases of non-small cell lung cancer[J].Chin J Oncol,2006,28(9):686-690.[董强刚,韩宝惠,黄进肃,等.176例非小细胞肺癌的EGFR基因突变分析[J].中华肿瘤杂志,2006,28(9):686-690.]
[12]Huang SF,Liu HP,Li LH,et al.High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan[J].Clin Cancer Res,2004,10(12):8195-8203.
[13]Mu XL,Li LY,Zhang XT,et al.Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer[J].Clin Cancer Res,2005,11(12):4289-4294.
[14]Qin BM,Chen X,Zhu JD,et al.Identification of EGFR kinase domain mutations among lung cancer patients in china:implication for targeted cancer therapy[J].Cell Res,2005,15(3):212-217.
[15]Dong DD,Tang Y,Zou Y,et al.Study of exons 19 and 21 mutations of epidermal growth factor receptor gene in patients with lung adenocarcinoma of Sichuan province[J].Chin J Clin Exp Pathol,2011,27(12):1306-1309.[董丹丹,唐源,邹艳,等.四川地区肺腺癌中 EGFR基因19,21外显子突变研究[J].临床与实验病理学杂志,2011,27(12):1306-1309.]
[16]Chen HJ,Yu CS,Li HB,et al.EGFR gene mutation status among NSCLC patients in Guangdong province[J].J Molecular Diagnosis and Therapy,2011,3(1):29-32.[陈慧娟,喻长顺,李洪波,等.广东地区非小细胞肺癌 EGFR基因的突变研究[J].分子诊断与治疗杂志,2011,3(1):29-32.]
[17]Tang YP,Zhang LT,Tan XY,et al.Analysis of EGFR mutations in non-small cell lung cancer in Nanning Guangxi China[J].Modern Oncology,2014,22(5):1067-1070.[唐艳萍,张力图,谭晓玉,等.广西南宁地区非小细胞肺癌 EGFR基因突变分析[J].现代肿瘤医学,2014,22(5):1067-1070.]
[18]Zhao J,Tian QM,Huang YM,et al.An analysis of the EGFR gene mutation in 238 patients with non-small cell lung cancer in Hunan province[J].Anti-tumor Pharmacy,2014,4(3):187-192.[赵瑾,田俏梅,黄玉梅,等.湖南地区 238 例非小细胞肺癌 EGFR 基因突变状态分析[J].肿瘤药学,2014,4(3):187-192.]
[19]Yang CS,Xu WM,Feng Q,et al.EGFR gene mutation of non-small cell lung cancer from different regions of Yunnan province[J].Medical J National Defending Forces in Southwest China,2016,26(1):4-7.[杨长绍,徐文漭,冯强,等.云南不同地区非小细胞肺癌EGFR基因突变检测分析[J].西南国防医药,2016,26(1):4-7.]
[20]Huang DM,Feng GS.Advances of combinations of different molecular targeted drugs in lung cancer secondary resistant to EGFR-TKIs[J].Chinese J New Clinical Medicine,2016,9(8):748-752.[黄东明,冯国生.分子靶向药物联合治疗EGFR-TKIs继发性耐药肺癌的研究进展[J].中国临床新医学,2016,9(8):748-752.]